2023
Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations
Rajwa P, Quhal F, Pradere B, Gandaglia G, Ploussard G, Leapman M, Gore J, Paradysz A, Tilki D, Merseburger A, Morgan T, Briganti A, Palapattu G, Shariat S. Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations. Nature Reviews Urology 2023, 20: 205-216. PMID: 36600087, DOI: 10.1038/s41585-022-00680-4.Peer-Reviewed Original ResearchConceptsProstate cancer riskBRCA1/2 mutation carriersMagnetic resonance imagingProstate cancerMutation carriersCancer riskProspective studyBRCA2 mutationsProstate cancer-specific mortalityProstate specific antigen measurementsCancer-specific mortalityProstate cancer incidenceAggressive clinical behaviorProstate cancer screeningRisk stratification strategiesLong-term resultsSignificant prostate cancerOptimal screening strategyGermline BRCA1/2 mutationsOptimal screening protocolProstate magnetic resonance imagingQuality of lifeBRCA2 tumor suppressor genesOverall survivalDisease characteristics
2019
National trends and pathologic outcomes of neoadjuvant chemotherapy among patients with micropapillary variant urothelial carcinoma of the bladder.
Javier-Desloges J, Abello A, Syed J, Leapman M. National trends and pathologic outcomes of neoadjuvant chemotherapy among patients with micropapillary variant urothelial carcinoma of the bladder. Journal Of Clinical Oncology 2019, 37: 477-477. DOI: 10.1200/jco.2019.37.7_suppl.477.Peer-Reviewed Original ResearchUse of NACUrothelial cell carcinomaReceipt of NACNeoadjuvant chemotherapyMicropapillary variantPathologic responseEntire cohortCell carcinomaClinical stage II diseasePropensity scoreVariant urothelial carcinomaNational Cancer DatabaseStage II diseaseComplete pathologic responsePathologic complete responseAggressive clinical behaviorLogistic regression modelsCT2 diseasePT0 rateComplete responsePathologic characteristicsRadical cystectomyDistant metastasisHistological diagnosisNAC use